Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.61 |
| ▸ | HTR5A | P47898 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8468658 | 0.85 | MEN1 (0.61) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL17650857 | 0.85 | OPRM1 (0.57) | MEN1KMT2AOPRM1OPRL1GRIN2B | |
| SCHEMBL17650859 | 0.85 | OPRM1 (0.57) | MEN1KMT2AOPRM1OPRL1GRIN2B | |
| SCHEMBL8468660 | 0.85 | MEN1 (0.61) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL5465162 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL5466092 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL5465166 | 0.84 | ALDH1A1 (0.55) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL7226427 | 0.82 | MEN1 (0.65) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL7952672 | 0.82 | MEN1 (0.65) | MEN1KMT2AOPRM1OPRL1HTR5A | |
| SCHEMBL7951355 | 0.82 | MEN1 (0.65) | MEN1KMT2AOPRM1OPRL1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589207-B2 | Cyclohexyl compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1569647-B1 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20060122166-A1 | Cyclohexyl compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-06-08 | — | — | US | disclosed |
| EP-1569647-A2 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004054581-A2 | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122166-A1 | Cyclohexyl compounds as ccr5 antagonists | CCR5, CCR1, CCR3 | MEN1 4748/4885KMT2A 4628/4885OPRM1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.